News
Follow us on LinkedIn and stay up-to-date with our latest news.
Dec 2024
Poster presentation at British Pharmacological Society (BPS)
Poster on clinical trial at CHDR with title “Intravaginal delivery of oxybutynin via the MedRing OAB: a double-blind three-way crossover study comparing intravaginal and oral oxybutynin administration”.
Nov 2023
Development of Companion App (BPS)
Smartphone application for iOS & Android for use in a 28-day clinical trial in an out-patient setting.
Feb 2023
First publication in human study
Online publication on LiGalli’s First in Human oxybutynin MedRing study showing favorable vaginal absorption and pharmacokinetics..
Our Milestones
Poster presentation Dutch Medicine Days Leiden
Abstract presented at Dutch Medicine Days 2025. Our CHDR-2222 clinical study in overactive bladder patients was presented at the FIGON/BPS Dutch Medicines Days in Leiden. The study demonstrated that the MedRing OAB system is a feasible alternative for personalized oxybutynin administration over 28 days in an outpatient setting.
Poster presentation International Congress Pharmaceutical Medicine in Amsterdam
The poster showcased the results of our multiple-dose pharmacokinetic and side-effect comparison study on the MedRing OAB (Oxybutynin).
Poster presentation at British Pharmacological Society (BPS)
Poster on clinical trial at CHDR with title “Intravaginal delivery of oxybutynin via the MedRing OAB: a double-blind three-way crossover study comparing intravaginal and oral oxybutynin administration”.
Development of Companion App
Smartphone application for iOS & Android for use in a 28-day clinical trial in an out-patient setting.
First publication in human study
Online publication on LiGalli’s First in Human oxybutynin MedRing study showing favorable vaginal absorption and pharmacokinetics.
Appointment of Unilever veteran Marga Mathijssen as CEO of LiGalli
Read all about it in our press release.
Development partner Demcon published an article on LiGalli in their internal Demcon Investment newsletter
You can read the article for more details.
LiGalli receives the International Life Sciences Award 2021
You can read the article for more details.
The basic MedRing patent is granted in China
The MedRing Alpha 1.0 is ready
The first in-human trials will start shortly.
The basic MedRing patent is granted
First in the EU, later also in the US.
The MedRing functional model is ready
The first working (desktop) model of the LiGalli MedRing to proof the working principle.
The Dutch Government awards LiGalli the MIT subsidy
We look forward to working with our new partner Gimix ('TwentyNext' per July 2022).
Sep 2022
Appointment of Unilever veteran Marga Mathijssen as CEO of LiGalli
Read all about it in our press release.
Dec 2021
Development partner Demcon published an article on LiGalli in their internal Demcon Investment newsletter
You can read the article for more details.
Sept 2021
LiGalli receives the International Life Sciences Award 2021
You can read the article for more details.
Apr 2021
The basic MedRing patent is granted in China
Sept 2020
The MedRing Alpha 1.0 is ready
The first in-human trials will start shortly.
March 2020
The basic MedRing patent is granted
First in the EU, later also in the US.
Feb 2020
The MedRing functional model is ready
The first working (desktop) model of the LiGalli MedRing to proof the working principle.
Dec 2019
The Dutch Government awards LiGalli the MIT subsidy
We look forward to working with our new partner Gimix(‘TwentyNext’ per July 2022).
"Our company owes its name to the 'Li Galli' island group in Italy - a mythical place where mermaids dwell - emphasizing women's empowerment, just like our company's products."
Get in touch
Office Address
Leiden Bio Science Park – BioPartner 3
Galileiweg 8, 2333 BD Leiden
The Netherlands
Postal Address
LiGalli B.V.
J.H. Oortweg 21, 2333 CH Leiden
The Netherlands